Judy Chou

Dr. Judy Chou is the President, CEO, and Board member of AltruBio, Inc. Before taking on her current roles, she headed the global biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s biotechnology product portfolio & 2000+ employees and leading the drug development and launch activities for biologics pipeline. In addition, she served as the site head for Bayer’s facility in Berkeley, CA. She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times. Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical at Pfizer, Inc. where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D and Manufacturing at Tanvex Biopharma and has enabled the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in biologics development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough technologies and accelerated product development.

Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc., an advisor of UC, Berkeley Engineering School, and an advisor of Silicon Valley Women in Engineering. Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her Ph.D. from Yale University.